The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH with Paricalcitol-centered Therapy vs. Cinacalcet Therapy with Low-dose Vitamin D in Hemodialysis Patients with Secondary Hyperparathyroidism
- Registry ID
- EUCTR2009-011378-14
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE4
- Sponsor
- Abbott GmbH & Co. KG
- Start date
- 2009-11-12
- Completion date
- 2011-06-17
- Last update
- 2026-08-16
Conditions
- Secondary hyperparathyroidism (SHPT)
- Secondary hyperparathyroidism (SHPT).
- Secondary hyperparathyroidism (SHPT) Hiperparatiroidismo secundario
Summary
To evaluate the superiority of paricalcitol as compared to cinacalcet with supplemental low dose vitamin D therapy, as assessed by the proportion of haemodialysis subjects that achieve a mean iPTH value between 150 to 300 pg/mL during Weeks 21 to 28.
Locations
- , , Sweden
- , , UK
- , , Czechia
- , , Portugal
- , , Netherlands
- , , Germany
- , , Spain
- , , Italy
- , , Greece
- , , Denmark
View on source registry